3.645

5.69% 0.205

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $3.645, with a volume of 687.70K. It is up +5.69% in the last 24 hours and up +18.81% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$3.44

Open:

$3.48

24h Volume:

687.70K

Relative Volume:

0.20

Market Cap:

$843.66M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-2.7406

EPS:

-1.33

Net Cash Flow:

$-159.16M

1W Performance:

-4.07%

1M Performance:

+18.81%

6M Performance:

+152.48%

1Y Performance:

+332.82%

1-Day Range:

$3.43

$3.705

1-Week Range:

$3.37

$3.865

52-Week Range:

$0.76

$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1135)

Industry

Biotechnology (633)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

145

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	3.645	796.21M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	458.40	115.75B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.86	80.71B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	410.05	52.88B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	852.79	52.64B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.19	37.29B	447.02M	-1.18B	-906.14M	-6.1812

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-10-25	Upgrade	UBS	Neutral → Buy
Jul-14-25	Initiated	Scotiabank	Sector Outperform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

Dec 21, 2025

Gossamer Bio, Inc.(NasdaqGS: GOSS) added to S&P Biotechnology Select Industry Index - marketscreener.com

Dec 21, 2025

Gap Down: Will Timberland Bancorp Inc stock outperform Nasdaq indexJuly 2025 Earnings & Low Volatility Stock Recommendations - moha.gov.vn

Dec 21, 2025

Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data - Finviz

Dec 21, 2025

Aug Decliners: Can Gossamer Bio Inc. stock deliver surprise earnings beatWeekly Profit Recap & Expert Curated Trade Setups - Улправда

Dec 21, 2025

Dec 19, 2025

Is Gossamer Bio Inc. stock attractive for income investorsJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - DonanımHaber

Dec 19, 2025

Gossamer Bio: High Risk Binary Approaches (NASDAQ:GOSS) - Seeking Alpha

Dec 19, 2025

Will Gossamer Bio Inc. stock reach Wall Street targetsJuly 2025 Highlights & Low Risk High Reward Ideas - DonanımHaber

Dec 19, 2025

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 19, 2025

Aug Swings: Can Gossamer Bio Inc. stock hit record highs againMarket Risk Report & Intraday High Probability Alerts - Улправда

Dec 19, 2025

Dec 18, 2025

Can Gossamer Bio Inc. stock deliver surprise earnings beatJuly 2025 Setups & Free Daily Entry Point Trade Alerts - Улправда

Dec 18, 2025

Dec 17, 2025

Gossamer Bio (NASDAQ:GOSS) Sets New 1-Year HighShould You Buy? - MarketBeat

Dec 17, 2025

Dec 16, 2025

Gossamer Bio (NASDAQ:GOSS) Stock Price Down 6.5%Time to Sell? - MarketBeat

Dec 16, 2025

Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Finviz

Dec 16, 2025

Dec 15, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 9, 2025 - BioSpace

Dec 10, 2025

Dec 09, 2025

Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 09, 2025